The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global elastomer infusion pump market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Elastomer infusion pumps are medical devices used to administer liquid drugs, such as chemotherapy, antibiotics, fluorouracil (5FU), analgesics, and anesthetics, intravenously depending on the therapy required. They contain balloon-like chambers that exert pressure to deliver drugs safely at a steady rate. Nowadays, elastomer infusion pumps that are disposable, compact, portable, and lightweight are widely available for residential purposes. Moreover, several manufacturers are offering products with high flow rate accuracy, minimal residual volume for complete drug administration, and an inline filter to reduce the risk of air embolism and particle contamination.
A rise in the prevalence of cancer on account of sedentary lifestyles, growing air pollution, and the increasing number of individuals who consume alcohol and smoke tobacco is resulting in the significant need for chemotherapy. This represents one of the primary factors impelling the market growth. In addition, as cellular repair is less effective in older individuals, the risk of developing cancer rises considerably with age. Consequently, the increasing geriatric population is acting as another significant growth-inducing factor. Apart from this, due to the growing cases of coronavirus disease (COVID-19), healthcare facilities across the globe are relying on elastomeric infusion pumps to ensure adequate treatment of critically ill patients. The use of disposable, single-infusion elastomeric pumps also reduces the risk of cross-contamination between patients and healthcare professionals. Moreover, the escalating number of orthopedic procedures and surgeries is influencing the need for elastomer infusion pumps for post-operative pain management. Furthermore, the increasing burden on hospitals, in confluence with shifting preferences towards home-based care, is stimulating the market for elastomer infusion pumps over conventional electric pumps worldwide.
IMARC Group provides an analysis of the key trends in each sub-segment of the global elastomer infusion pump market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Avanos Medical Inc., B. Braun Melsungen AG, Baxter International Inc., Daiken Medical Co. Ltd., Nipro Corporation, O&M Halyard Inc, Palex Medical S.A., Pfizer Inc. (Hospira Inc.), pfm medical ag., Samtronic Industria e Comercio LTDA, Smiths Group plc. and Woo Young Medical Co. Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Avanos Medical Inc., B. Braun Melsungen AG, Baxter International Inc., Daiken Medical Co. Ltd., Nipro Corporation, O&M Halyard Inc, Palex Medical S.A., Pfizer Inc. (Hospira Inc.), pfm medical ag., Samtronic Industria e Comercio LTDA, Smiths Group plc. and Woo Young Medical Co. Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at